O’RIGHT
18.11.2020 10:02:09 CET | Business Wire | Press release
As the novel coronavirus spreads across the world, Taiwanese green beauty brand O’right continues to make significant strides in sustainability. This year, O’right made headlines with the opening of its store in Isetan Shinjuku, a leading department store in Japan. Now, the pioneering brand has made its way into Lyko, a Sweden-based beauty and hair care chain that has quickly become the Nordic region’s leading player in the segment. Recently, the green innovator celebrates the Good Design Gold Award (Japan’s Good Design Award is one of the top 4 design awards in the world) honor for its latest innovation – the world’s greenest toothpaste – to offer new green lifestyle solutions worldwide. O’right continues its commitment to doing what’s best for people, the society and earth and calls on businesses and people to follow suit. What started as a small, unknown name in Taiwan has now evolved into a zero carbon beauty brand that is taking the beauty sector by storm.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005486/en/
A visionary brand that’s here to stay
O’right and the Swedish beauty retailer Lyko first crossed paths at Cosmoprof Bologna. Founded in the world’s most sustainable country, Lyko partners with brands and stocks products that align with its own values and meets its high standards. O’right has been leading the way to sustainability for years, from its innovative 8 Free standard for creating non-toxic, clean and multi-award-winning range of green products to recently receiving the USDA Certified Biobased Product Label. This year, the company aims to achieve zero carbon (carbon neutrality) for 77 of its products. O’right’s commitment to sustainability is shown not only in its values, but also from product formulations to packaging. The trailblazer demonstrates a positive social and environmental impact and powerful visionary narratives that justify its worth and inspire the Swedish-based chain to wholeheartedly invest in. It’s safe to say that the cosmetic world is excited to watch as the partnership between two companies that share the same values from the East and the West blossoms into something incredible.
Green without borders
Lyko boasts Sweden’s largest e-commerce site with an average monthly traffic count of 4 million visits, along with 37 physical stores in Sweden and Norway. Lyko joins forces with O’right, opening the door for the Taiwanese brand to make its green values and products seen in the Nordic region. O’right green products even made it into the e-commerce platform’s top sellers list. As a green zero carbon brand, O’right believes that the key to making a greater influence in every part of the world is to inspire green living and consumption. When it comes to sustainability, distance and national borders don’t matter.
Does O’right, a small Taiwanese company from the small land of Taiwan, have what it takes to conquer the eco beauty sector of the Nordic region? O’right is determined to show its green value and wow consumers with its holistic green lifestyle solutions and innovative trends.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005486/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom